Todos Medical

Diagnostic Testing Solutions for the Immune System

Health Tech & Life Sciences
Public on OTCBB on Feb 2016

Company Overview

Snapshot

Founded in November 2009, Todos Medical is a public company with 1–10 employees. It has raised $3.45M across four funding rounds from two investors. In April 2021, Todos Medical acquired Provista Diagnostics, expanding its portfolio of diagnostic solutions.

Business overview

Todos Medical develops diagnostic testing solutions focused on the early detection of various cancers and neurodegenerative disorders like Alzheimer's disease. The company's core technology, Todos Biochemical Infrared Analyses (TBIA), utilizes proprietary cancer-screening technology that analyzes peripheral blood for biochemical changes in immune system components. Todos Medical also develops diagnostic blood tests such as the Lymphocyte Proliferation Test and has expanded into distributing COVID-19 test kits, serving the health tech and life sciences sectors.

Strategic signal

In September 2023, Todos Medical announced a corporate retooling to focus on the Long COVID epidemic. This strategic pivot indicates the company's responsiveness to emerging public health challenges and its intent to leverage its diagnostic expertise to address a significant and growing medical need, potentially opening new market opportunities and revenue streams for investors.

Company Intelligence Q&A

What was a significant strategic acquisition made by Todos Medical?
In April 2021, Todos Medical acquired.
What was a key strategic focus announced by Todos Medical in September 2023?
In September 2023, Todos Medical announced a corporate retooling initiative to focus on addressing the Long COVID epidemic, signaling a strategic shift towards emerging health challenges.
When did Todos Medical receive patent allowances for its AI-based diagnostics platform?
In September 2022, Todos Medical received two Notices of Allowance from the USPTO for its AI-Based TBIA Pan-Cancer Blood Diagnostics Platform.
What was a notable partnership formed by Todos Medical in 2020 related to COVID-19?
In September 2020, Todos Medical formed a joint venture with NLC Pharma, adding the 3CL Protease Inhibitor NLC-001 to their COVID-19 focused efforts.
What was the outcome of Todos Medical's pilot launch for PCR testing services?
In October 2022, Todos Medical announced the successful pilot launch of a suite of PCR testing services by its CLIA/CAP Lab, Provista Diagnostics.

External links